1. Efficient Differentiation of Human Induced Pluripotent Stem Cells into Endothelial Cells under Xenogeneic-free Conditions for Vascular Tissue Engineering
- Author
-
Christopher W. Anderson, Yifan Yuan, Juan Wang, Mehmet H. Kural, Yuyao Lin, Jiesi Luo, Xiangyu Shi, Matthew W. Ellis, Yibing Qyang, Muhammad Riaz, Laura E. Niklason, and Shang-Min Zhang
- Subjects
Induced Pluripotent Stem Cells ,0206 medical engineering ,Cell ,Biomedical Engineering ,02 engineering and technology ,Biochemistry ,Article ,Biomaterials ,Immune system ,medicine ,Animals ,Humans ,Human Induced Pluripotent Stem Cells ,Molecular Biology ,Tissue engineered ,Decellularization ,Tissue Engineering ,Chemistry ,Endothelial Cells ,Cell Differentiation ,General Medicine ,021001 nanoscience & nanotechnology ,020601 biomedical engineering ,In vitro ,Blood Vessel Prosthesis ,Cell biology ,medicine.anatomical_structure ,Time course ,Vascular tissue engineering ,0210 nano-technology ,Biotechnology - Abstract
Tissue engineered vascular grafts (TEVGs) represent a promising therapeutic option for emergency vascular intervention. Although the application of small-diameter TEVGs using patient-specific primary endothelial cells (ECs) to prevent thrombosis and occlusion prior to implantation could be hindered by the long time course required for in vitro endothelialization, human induced pluripotent stem cells (hiPSCs) provide a robust source to derive immunocompatible ECs (hiPSC-ECs) for immediate TEVG endothelialization. To achieve clinical application, hiPSC-ECs should be derived under culture conditions without the use of animal-derived reagents (xenogeneic-free conditions), to avoid unwanted host immune responses from xenogeneic reagents. However, a completely xenogeneic-free method of hiPSC-EC generation has not previously been established. Herein, we substituted animal-derived reagents used in a standard method of xenogeneic hiPSC-EC differentiation with functional counterparts of human origin. As a result, we generated xenogeneic-free hiPSC-ECs (XF-hiPSC-ECs) with similar marker expression and function to those of human primary ECs. Furthermore, XF-hiPSC-ECs functionally responded to shear stress with typical cell alignment and gene expression. Finally, we successfully endothelialized decellularized human vessels with XF-hiPSC-ECs in a dynamic bioreactor system. In conclusion, we developed xenogeneic-free conditions for generating functional hiPSC-ECs suitable for vascular tissue engineering, which will further move TEVG therapy toward clinical application.
- Published
- 2021